This blog was written by Sam Truex, former CBO of Padlock and Synlogics, and current Atlas EIR, as part of the From the Trenches feature of LifeSciVC. Funding for biotech companies has been abundant this year. As covered the first

This blog was written by Jason Gardner, CEO and co-founder of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC.            There’s a proverb that goes like this, “If you want to go

We’re excited to announce the launch of Science2Startup, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. This event is in many ways a relaunch of the successful URES (University Research

Today Nimbus and Celgene announced a significant partnership focused on autoimmune and inflammatory diseases. The alliance includes two pre-clinical autoimmune-focused programs in various stages of drug discovery. The most advanced program is a highly selective inhibitor of Tyk2, an immunokinase

Private biotech funding numbers are in for the third quarter and on an absolute capital basis they are huge: $3.6B flowed into private biotechs, the largest quarter of VC-funding into biopharma ever in the history of our industry, according to

Building a shared sense of community helps create the relationships and interactions that bring people together and make teams and sector ecosystems successful. Community is a core part of building a distinctive culture. With a portfolio of related investments, industry

Neuroscience has quietly become a hot space for startups. Across a range of neurologic conditions, contrarian investors have been fueling entrepreneurs to discover and develop novel therapeutic strategies. Earlier this week, two Atlas-founded companies, Rodin Therapeutics and Disarm Therapeutics, both announced

Last month, Bloomberg bemoaned the dearth of biotech M&A, and pundits echoed the sentiment (here, here), citing concerns about tax rates and drug pricing. The top line numbers in Bloomberg’s graph certainly paint a dim view of 2017’s global biotech

It’s all about people, it always is. Human capital is a company’s most important asset. Successful companies have human capital management strategies that excel at talent recruitment, and prioritize career development and retention. But human capital is never static, and

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. On my first morning as a US-based employee, I took advantage of the hotel’s shopping service by ordering the

Today BMS announced the acquisition of IFM Therapeutics, an emerging biotech focused on modulating core innate immune pathways to treat cancer and autoimmune disease. As described in the press release, BMS will acquire the company for $300M upfront, with potentially

Corporate culture is often hard to precisely define. Yet it’s always cited as being one of the key drivers of company outperformance, especially for startups. Recently I was asked to define what culture means by a young entrepreneur: beyond the